ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Diagnostic Test Accuracy of Cytosponge-Trefoil Factor 3 for Barrett Esophagus: A Systemic Review and Meta Analysis.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review of Gastrointestinal Capsule Robots: Materials, Actuation, Diagnostics, and Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The evolving role of OMICS in gastrointestinal tumor biology and clinical practice.Molecular cancer · 2026Review
- Liquid Biopsy and Nonendoscopic Biomarkers for Precision Early Detection of Esophageal Cancer: Evidence, Risk Stratification and Translational Challenges.Journal of Cancer · 2026Review
- Diagnostic Test Accuracy of Cytosponge-Trefoil Factor 3 for Barrett Esophagus: A Systemic Review and Meta Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Barrett's esophagus (BE), characterized by the replacement of normal esophageal squamous epithelium with columnar metaplasia, poses a risk of progression to esophageal adenocarcinoma. Early detection is essential to prevent malignant transformation. The Cytosponge, a novel, minimally invasive cell collection device, has been proposed as a diagnostic tool for BE by identifying trefoil factor 3 (TFF3)-positive cells. This meta-analysis evaluates the diagnostic accuracy of the Cytosponge technique for detecting BE. Methods: A systematic literature search was performed using PubMed and Web of Science for studies published up to May 2024. Two reviewers independently screened studies, extracted data, and assessed the risk of bias using the QUADAS-2 tool. A bivariate random-effects model was used to estimate pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence intervals (CIs). Summary receiver operating characteristic (SROC) curves were generated. Results: Six studies comprising 3438 participants were included. For detecting BE with circumferential length > 1 cm (C1), pooled sensitivity and specificity were 0.75 (95% CI: 0.70-0.79) and 0.88 (95% CI: 0.76-0.94), respectively, with an area under the SROC curve (AUC) of 0.80 (0.77-0.84). For any circumferential length of metaplasia, sensitivity and specificity were 0.81 (95% CI: 0.76-0.85) and 0.89 (95% CI: 0.82-0.93), with an AUC of 0.90 (0.87-0.92). Conclusion: The Cytosponge demonstrates high diagnostic accuracy for detecting BE, especially for any length of metaplasia. Further large-scale studies are warranted to validate its routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.